Cutaneous adverse events induced by azacitidine in myelodysplastic syndrome patients: Case reports and a lesson from published work review
- 1 April 2020
- journal article
- review article
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (4), 363-368
- https://doi.org/10.1111/1346-8138.15264
Abstract
Subcutaneous injection of azacitidine (AZA) is an important treatment option for myelodysplastic syndrome (MDS), which improves overall survival. In hematology, the incidence of AZA-induced cutaneous adverse events (AE) has been known to be relatively high, which has not been well recognized by dermatologists. Discontinuation of AZA can result in the deterioration of MDS disease activity. Therefore, on dermatological consultation, precise evaluation of AE severity and careful consideration is required for post-AE medication management. To enhance our understanding of AZA-induced cutaneous AE, we report four cases with two representative cutaneous AE subtypes and summarize the clinicopathological phenotypes and courses of the cases in the published work. Case 1, a 71-year-old man, developed neutrophilic dermatosis involving the dermis and subcutaneous tissue. The other three cases, a 75-year-old man, a 78-year-old woman and a 68-year-old man, presented injection-site erythema associated with flare-up reaction. Discontinuation of AZA was necessary for case 1 alone. The published work review delineated three major subtypes of AZA-induced cutaneous AE: systemic cutaneous reaction, neutrophilic dermatosis type and erythematous type injection-site reaction. Histologically, the first two subtypes are mostly characterized by neutrophil infiltration, while the third subtype presents lymphocytic cell infiltration. Neither AZA discontinuation nor intensive interventions were required for the erythematous type injection-site reaction, while AZA termination or systemic treatments, represented by corticosteroid administration, were preferentially conducted for the systemic cutaneous reaction or the neutrophilic dermatosis type injection-site reaction subgroup. These observations support the necessity of subtype-dependent treatment strategies for the management of AZA-induced cutaneous AE.Keywords
Funding Information
- Ministry of Health Labor and Welfare
This publication has 21 references indexed in Scilit:
- Azacitidine is effective for the treatment of myelodysplastic syndrome and accompanied Sweet syndromeAnnals of Hematology, 2015
- Complete remission of Sweet’s syndrome after azacytidine treatment for concomitant myelodysplastic syndromeInternational Journal of Hematology, 2014
- Injection-Site Reaction Following 5-Azacitidine InjectionAnnals of Dermatology, 2014
- Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndromeEuropean Journal of Haematology, 2013
- Case of azacitidine-induced maculopapular erythematous eruptionThe Journal of Dermatology, 2013
- Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisoloneLeukemia Research, 2012
- Azacitidine-associated Sweet’s syndromeAmerican Journal of Health-System Pharmacy, 2012
- Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*European Journal of Haematology, 2010
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009